Impact of the number of postoperative pathological lymph node metastasis areas on prognosis of thoracic esophageal squamous cell carcinoma

doi:10.3760/cma.j.cn371439-20200923-00016

Abstract

Abstract:

Objective To explore the impact of the number of pathological lymph node metastasis areas on the prognosis of patients with thoracic esophageal squamous cell carcinoma (ESCC) after radical surgery. Methods The clinicopathologic data of 153 patients with ESCC treated by radical surgery at the Department of Thoracic Surgery of the Affiliated Taixing People's Hospital of Yangzhou University from January 2012 to December 2014 were retrospectively analyzed. Among these patients, 76 had no adjuvant therapy, and 77 received adjuvant radiotherapy or chemoradiotherapy after surgery. According to the lymph node classification criteria of American Thoracic Association and the number of pathological lymph node metastasis areas, the patients were divided into non-regional lymph node metastasis group (n=68), oligo-regional lymph node metastasis group (1-2 regional lymph node metastasis, n=54) and multi-regional lymph node metastasis group (≥3 regional lymph node metastasis, n=31). Kaplan-Meier method was used to calculate survival rate and survival comparison was performed by log-rank test. The Cox proportional hazards model was used to analyze prognostic factors, receiver operating characteristic (ROC) curve was used to analyze the predictive value of the number of lymph node metastasis areas. Results The median overall survival (OS) was 37.0 months for the 153 patients, and the 1-, 3- and 5-year OS rates were 97.4%, 51.0% and 30.7% respectively. In the non-regional lymph node metastasis group, the median OS was 46.0 months, and the 1-, 3- and 5-year OS rates were 97.1%, 58.8% and 39.7% separately. In the oligo-regional lymph node metastasis group, the median OS was 39.0 months, and the 1-, 3- and 5-year OS rates were 94.4%, 55.6% and 35.2% respectively. In the multi-regional lymph node metastasis group, the median OS was 26.0 months, and the 1-, 3- and 5-year OS rates were 98.1%, 25.8% and 3.2% separately. There was a statistically significant difference among the three groups (χ²=18.257, P<0.001). Among the 76 patients without adjuvant treatment, the 1-, 3- and 5-year OS rates were 94.7%, 50.0% and 34.2% in patients with non-regional lymph node metastasis, 90.9%, 36.4% and 9.1% in patients with oligo-regional lymph node metastasis, 97.4%, 18.8% and 0 in patients with multi-regional lymph node metastasis, and there was a statistically significant difference (χ²=8.201, P=0.017). Among the 77 patients with adjuvant therapy, the 1-, 3- and 5-year OS rates were 97.7%, 66.7% and 46.7% in patients with non-regional lymph node metastasis, 96.9%, 68.8% and 53.1% in patients with oligo-regional lymph node metastasis, 93.3%, 26.7% and 6.7% in patients with multi-regional lymph node metastasis, and there was a statistically significant difference (χ²=18.083, P<0.001). Univariate analysis showed that age (HR=1.534, 95%CI: 1.041-2.260, P=0.030), T stage (HR=1.757, 95%CI: 1.197-2.579, P=0.004), N stage (HR=1.548, 95%CI: 1.043-2.297, P=0.030), TNM stage (HR=1.392, 95%CI: 1.114-2.459, P=0.015), adjuvant therapy (HR=0.545, 95%CI: 0.370-0.803, P=0.002) and number of lymph node metastasis areas (multi-regional lymph node metastasis versus non-regional lymph node metastasis: HR=0.385, 95%CI: 0.238-0.624, P<0.001; multi-regional lymph node metastasis versus oligo-regional lymph node metastasis: HR=0.442, 95%CI: 0.269-0.726, P=0.001) were closely related to OS in patients with ESCC after operation. Multivariate analysis showed that T stage (HR=1.699, 95%CI: 1.143-2.525, P=0.009), adjuvant therapy (HR=0.577, 95%CI: 0.386-0.864, P=0.008) and number of lymph node metastasis areas (multi-regional lymph node metastasis versus non-regional lymph node metastasis: HR=0.553, 95%CI: 0.411-0.996, P=0.011; multi-regional lymph node metastasis versus oligo-regional lymph node metastasis: HR=0.550, 95%CI: 0.328-0.924, P=0.024) were independent prognostic factors for OS. The number of lymph node metastasis areas (AUC=0.648, 95%CI: 0.560-0.735, P=0.004) was better than the number of lymph node metastasis (AUC=0.595, 95%CI: 0.497-0.694, P=0.061) in predicting OS of patients with ESCC after radical surgery. Conclusion The number of postoperative pathological lymph node metastasis areas in thoracic ESCC has important value in predicting survival prognosis, and adjuvant therapy can significantly improve the OS of patients with oligo-regional lymph node metastasis.

Key words: Esophageal neoplasms, Postoperative period, Prognosis, Number of lymph node metastasis areas

Guo Xinwei, Zhang Han, Ji Shengjun, Zhou Shaobing, Zhou Juying, Liu Yangchen, Gao Fei. Impact of the number of postoperative pathological lymph node metastasis areas on prognosis of thoracic esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2021, 48(2): 86-91.

Figures/Tables 7

References 10

[1]	Vizcaino AP, Moreno V, Lambert R, et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995[J]. Int J Cancer, 2002,99(6):860-868. DOI: 10.1002/ijc.10427. doi: 10.1002/ijc.10427 pmid: 12115489
[2]	Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Can-cer Staging Manual: esophagus and esophagogastric junction[J]. Ann Surg Oncol, 2010,17(7):1721-1724. DOI: 10.1245/s10434-010-1024-1. doi: 10.1245/s10434-010-1024-1 pmid: 20369299
[3]	安丰山, 黄金球, 陈少湖. 217例胸段食管癌淋巴结转移及其对预后影响的分析[J]. 癌症, 2003,22(9):974-977.
[4]	Casson AG, Rusch VW, Ginsberg RJ, et al. Lymph node mapping of esophageal cancer[J]. Ann Thorac Surg, 1994,58(5):1569-1570. DOI: 10.1016/0003-4975(94)91986-0. doi: 10.1016/0003-4975(94)91986-0 pmid: 7979715
[5]	Wang Y, Zhu L, Xia W, et al. Anatomy of lymphatic drainage of the esophagus and lymph node metastasis of thoracic esophageal cancer[J]. Cancer Manag Res, 2018,10:6295-6303. DOI: 10.2147/CMAR.S182436. doi: 10.2147/CMAR.S182436 pmid: 30568491
[6]	Duan XF, Tang P, Shang XB, et al. The prevalence of lymph node metastasis for pathological T1 esophageal cancer: a retrospective study of 143 cases[J]. Surg Oncol, 2018,27(1):1-6. DOI: 10.1016/j.suronc.2017.11.002. doi: 10.1016/j.suronc.2017.11.002 pmid: 29549895
[7]	王永岗, 汪良骏, 张德超, 等. 胸段食管鳞癌淋巴结转移特点及临床意义[J]. 中华肿瘤杂志, 2000,22(3):241-243.
[8]	Xu QR, Zhuge XP, Zhang HL, et al. The N-classification for esophageal cancer staging: should it be based on number, distance, or extent of the lymph node metastasis?[J]. World J Surg, 2011,35(6):1303-1310. DOI: 10.1007/s00268-011-1015-9. doi: 10.1007/s00268-011-1015-9
[9]	Zhang W, Liu X, Xiao Z, et al. Postoperative intensity-modulated radiotherapy improved survival in lymph node-positive or stage Ⅲ thoracic esophageal squamous cell carcinoma[J]. Oncol Res Treat, 2015,38(3):97-102. DOI: 10.1159/000375391. doi: 10.1159/000375391 pmid: 25792080
[10]	Semenkovich TR, Subramanian M, Yan Y, et al. Adjuvant therapy for node-positive esophageal cancer after induction and surgery: a multisite study[J]. Ann Thorac Surg, 2019,108(3):828-836. DOI: 10.1016/j.athoracsur.2019.04.099. doi: 10.1016/j.athoracsur.2019.04.099 pmid: 31229485

参数	HR值	95%CI	P值
年龄(<63岁/≥63岁)	1.534	1.041~2.260	0.030
性别(男/女)	1.323	0.826~2.117	0.243
位置(中上段/下段)	1.285	0.952~1.729	0.097
分化程度(低分化/中高分化)	0.598	0.323~1.117	0.107
T分期(T_1-2/T_3-4)	1.757	1.197~2.579	0.004
N分期(N₀/N_1-2)	1.548	1.043~2.297	0.030
TNM分期(Ⅰ-Ⅱ/Ⅲ)	1.392	1.114~2.459	0.015
辅助治疗(无/有)	0.545	0.370~0.803	0.002
淋巴结转移区域数目
多区域淋巴结转移/ 无区域淋巴结转移	0.385	0.238~0.624	<0.001
多区域淋巴结转移/ 寡区域淋巴结转移	0.442	0.269~0.726	0.001

参数	HR值	95%CI	P值
年龄(<63岁/≥63岁)	1.233	0.991~2.510	0.068
T分期(T_1-2/T_3-4)	1.699	1.143~2.525	0.009
N分期(N₀/N_1-2)	1.421	0.255~7.917	0.689
辅助治疗(无/有)	0.577	0.386~0.864	0.008
淋巴结转移区域数目
多区域淋巴结转移/ 无区域淋巴结转移	0.553	0.411~0.996	0.011
多区域淋巴结转移/ 寡区域淋巴结转移	0.550	0.328~0.924	0.024

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[11]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[12]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[13]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[14]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[15]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.